Caprock Group’s Elicio Therapeutics ELTX Stock Holding History

Caprock Group’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,573	Closed	-$9.12K	–	671
2023 Q1	$9.12K	Hold	1,573	–	–	﹤0.01%	640
2022 Q4	$12.8K	Hold	1,573	–	–	﹤0.01%	552
2022 Q3	$14K	Hold	1,573	–	–	﹤0.01%	568
2022 Q2	$18K	Hold	1,573	–	–	﹤0.01%	547
2022 Q1	$33K	Hold	1,573	–	–	﹤0.01%	599
2021 Q4	$46K	Hold	1,573	–	–	﹤0.01%	577
2021 Q3	$154K	Hold	1,573	–	–	0.01%	513
2021 Q2	$205K	Hold	1,573	–	–	0.02%	492
2021 Q1	$284K	Buy	+1,573	New	+$304K	0.03%	351

Other funds holding ELTX

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MHC

Meyer Handelman Company Rye Brook, New York $3.22B AUM 24.51% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

SPIA

Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Caprock Group's ELTX Position: Q2 2023 in Review

Caprock Group sold out of Elicio Therapeutics (ELTX) in Q2 2023, closing a stake of 1,573 shares — an estimated $9.12K sold.

Caprock Group first reported a position in ELTX in Q1 2021 and held it in 9 quarters. The position peaked at $284K in Q1 2021. 15 funds tracked by Wall St. Rank hold ELTX as of Q2 2023.

Caprock Group reported no remaining Elicio Therapeutics position as of Q2 2023 after selling out during the quarter.
Caprock Group sold 1,573 Elicio Therapeutics shares in Q2 2023, an estimated $9.12K.
Caprock Group first reported a position in Elicio Therapeutics in Q1 2021 and held it in 9 quarters.
Caprock Group's Elicio Therapeutics position peaked at $284K in Q1 2021.
15 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q2 2023.

Based on Caprock Group's 13F filing for Q2 2023, filed 10 Aug 2023.